I am a buyer, and long term in rgdx, keep adding to my new position. I have only been here since the recent news. But the low float, coupled with the fact that Glaxo Smith Kline owns 8 m shares keeps me interested long term. Kudos that Blue Cross, Multiplan and Medicare reimburse for the testing. The recent acquisition adds depth and a stream of revenue which should change the balance sheet immediately, so we sit at 2.2399 but the Joneses know better.